Journal
MARINE POLLUTION BULLETIN
Volume 135, Issue -, Pages 1079-1084Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.marpolbul.2018.08.036
Keywords
Emerging contaminants; Water framework directive; Pharmaceuticals; Surface waters; Estuary; Portugal
Funding
- Fundacao para a Ciencia e a Tecnologia (FCT) [UID/MAR/04292/2013, SFRH/BPD/95784/2013, SFRH/BPD/94638/2013, SFRH/BPD/115162/2016]
- FCT BCC [PTDC/MAR-EST/3048/2014]
- Fundação para a Ciência e a Tecnologia [SFRH/BPD/115162/2016, SFRH/BPD/95784/2013] Funding Source: FCT
Ask authors/readers for more resources
We investigated the presence of 66 human and veterinary pharmaceuticals from seven therapeutic groups in surface waters of the Tejo estuary. Collection sites covered the entire estuary and included areas near main river inflows and wastewater treatment outfalls, traversing urban, agriculture, aquaculture, and nature reserve areas. Detection of pharmaceuticals was performed via UHPLC-TOF-MS. Pharmaceuticals were found in all sites (32 different compounds in total). Antibiotics, beta-blockers, antihypertensives and anti-inflammatories were the most frequently detected ( > 90%), with variation in concentrations reflecting the multifaceted nature of estuarine surroundings (accumulated site contamination between 15 and 351 ng L-1). Higher concentrations of antidepressant Sertraline (304 ng L-1), non-steroidal anti-inflammatory Diclofenac (51.8 ng L-1), lipid regulator Gemfibrozil (77.0 ng L-1), antihypertensive Ibersartan (161.9 ng L-1) or antibiotic Doxycycline (128.0 ng L-1), among others, though localized may potentially impact key estuarine functions or services. Ultimately, results provide a baseline for regulatory information and future biota evaluations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available